Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 20, 2014
Pharmacy Choice - News - Over-the-Counter Drugs - December 20, 2014

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 15 of 15     Go To Page:

12/19/14 - AbbVie Receives U.S. FDA Approval of VIEKIRA PAK? (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK?, an all-oral, interferon-free treatment, with or without ribavirin, for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis. "We are proud of the work of our research and development organization to bri
12/19/14 - Enanta Announces U.S. Food and Drug Administration Approves AbbVie's VIEKIRA PAK? (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced the U.S. Food and Drug Administration has approved AbbVie s VIEKIRA PAK? with or without ribavirin for the treatment of genotype 1 patients with chronic hep
12/19/14 - iGrow Hair Growth System Attains FDA Over-the-Counter Clearance [Health & Beauty Close - Up]
Apira Science said that the FDA has granted the company over-the- counter clearance for its iGrow Hair Growth System to effectively promote hair growth in women with Fitzpatrick skin phototypes I to IV and with Ludwig Baldness Scale Classifications of I to II. "More than 40 million women suffer from genetic hair loss, yet iGrow is one of just a ha
12/19/14 - Public Meeting on Patient-Focused Drug Development for Breast Cancer; Request for Comments
The public meeting is intended to allow FDA to obtain patient perspectives on the impact of breast cancer on daily life and patient views on treatment approaches. Submit written comments to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the d
12/18/14 - Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com
SAN DIEGO, CA/ ACCESSWIRE/ December 18, 2014/ Innovus Pharmaceuticals, Inc., an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today its recent interview with TheStockRadio.com, Inc. an audio.
12/17/14 - Ipsen Announces the FDA Approval of Somatuline Depot (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot Injection 120 mg was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to.
12/17/14 - Nutra Pharma Announces Manufacturing Release of Pet Pain-Away and Delivery of Initial Orders
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away?. The Company also announced that they have begun shipping and ma
12/17/14 - Therabron Therapeutics, Inc. Secures Up to $11M in Series B Financing
Therabron Therapeutics, Inc., a privately held clinical-stage biotechnology company, today announced that it has secured an investment of up to $11.1 M in multiple tranches of a Series B Financing from Brace Pharmaceuticals LLC, Zell Biotech Two LLC, and three other investors. The Maryland- based company plans to initiate a second trial for its CG2
12/16/14 - GNW-News: Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder (english)
Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder. Novartis International AG/ Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder. Processed and transmitted by NASDAQ OMX Corporate Solutions.
12/16/14 - iGrow Hair Growth System Receives FDA Over-the-Counter Clearance for Women
Apira Science, Inc. today announced the FDA has granted the company over-the-counter clearance for its iGrow Hair Growth System to effectively promote hair growth in women with Fitzpatrick skin phototypes I to IV and with Ludwig Baldness Scale Classifications of I to II. The hands-free, in-home hair growth device is now widely available without
12/16/14 - Ipsen Announces the FDA Approval of Somatuline Depot (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot Injection 120 mg was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to.
12/16/14 - Ipsen's Somatuline Depot is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Ipsen today announced that Somatuline Depot Injection 120 mg was approved by the U.S. Food and Drug Administration for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. Marc de Garidel, Chairman and Chief Executive Officer of Ipse
12/16/14 - Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release* for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. The approval of Signifor LAR, a next-generation som
12/15/14 - American Regent's Injectafer (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services
American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc., announced today that the Centers for Medicare& Medicaid Services has granted a Healthcare Common Procedure Coding System code, or permanent J code, for Injectafer , the first and only high-dose non-dextran intravenous iron for treatment of iron deficiency anemia due to vario
12/15/14 - VIVUS Announces Favorable Formulary Positioning for Qsymia
VIVUS, Inc., a biopharmaceutical company commercializing Qsymia capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL. Preferred brand-name medicines are listed on the PDL to help identify products that are clinically appropriate and...
Articles(s): 1 - 15 of 15     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
Medication Errors: A Patient Safety and Quality Improvement Program
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415